Clinical significance of cytogenetic abnormalities in uterine myomas

被引：58

作者：

Brosens, I ^{[1
]}

Deprest, J ^{[1
]}

Dal Cin, P ^{[1
]}

Van den Bergh, H ^{[1
]}

机构：

[1] Univ Hosp Gasthuisberg, B-3000 Louvain, Belgium

来源：

FERTILITY AND STERILITY | 1998年 / 69卷 / 02期

关键词：

myoma; cytogenics; GnRH-agonist; ovarian steroid hormones;

D O I：

10.1016/S0015-0282(97)00472-X

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

Objective: To investigate the clinical characteristics of uterine myomas with cytogenetic rearrangements. Design: Comparative study of myomas with normal and abnormal karyotype. Setting: University hospital. Patients: Premenopausal, GnRH-agonist (GnRH-a) treated and menopausal patients. Interventions: Myomectomy or hysterectomy. Main Outcome Measures: Karyotype analysis and clinical characteristics. Results: Clonal abnormalities occurred in 29% of uterine myomas but were not related to the age of the patient or, in untreated menopausal patients, to the size of the myoma. In GnRH-a treated and menopausal women, 48% of the myomas larger than 4 cm were associated with clonal abnormalities. Submucous myomas had significantly fewer clonal abnormalities (12%) than subserosal (29%) or intramural myomas (35%). Conclusion: The data support the hypothesis that cytogenetic rearrangements in uterine myomas are associated with loss of steroid hormones dependency and alter the growth potential of the tumor. (C) 1998 by American Society for Reproductive Medicine.

引用

页码：232 / 235

页数：4

共 15 条

[1] Analysis of the karyotype and desoxyribonucleic acid content of uterine myomas in premenopausal, menopausal, and gonadotropin-releasing hormone agonist-treated females [J].